Breaking News! Realbio Incorporated into the "Blue Book of Tumor Molecular Diagnostic Industry Development"! (Including the full text access method)

Molecular diagnostics has become one of the key solutions in the cancer treatment process, from early screening and diagnosis tools for high-risk and healthy populations to precision drug guidance for patients with advanced cancer, as well as assessing the risk of recurrence by detecting microscopic residual lesions in cancer patients. The clinical application value of molecular diagnostics is gradually permeating into the intervention and management of the entire life cycle of cancer.

In recent years, the molecular diagnostics industry has shown a positive development trend in terms of technological development, policy support, market demand, and industry cooperation. Molecular diagnostics companies have been translating their research findings into practical clinical applications, continuously accumulating strength in technology development, product quality, and service levels, and continuously promoting the introduction of high-quality and clinically precise molecular diagnostics products that benefit the public.

Frost & Sullivan (hereinafter referred to as "Frost & Sullivan" or "Sullivan") has written the "Blue Book of Tumor Molecular Diagnostic Industry Development" (hereinafter referred to as the "Blue Book"), aiming to analyze the current status of the tumor molecular diagnostic industry, track the development of the industry and technology, explore the great potential of industry development, and analyze the driving factors behind market development, in order to provide a reference for participants and stakeholders in the tumor molecular diagnostic field.

On March 26th, Sullivan hosted an online launch event for the "Blue Book of Tumor Molecular Diagnostic Industry Development," interpreting and sharing the content of the "Blue Book," and inviting representatives from the tumor molecular diagnostic industry to discuss hot topics such as R&D challenges and technological innovations.

5

Company Introduction in the Field of Tumor Molecular Diagnostics

Realbio P66-67 of the "Blue Book of Tumor Molecular Diagnostic Industry Development"

Realbio is a professional company engaged in the development of precise tumor detection products. It currently has branches in Hangzhou, Qingdao, and Hunan. Ruiyi Biotech is committed to the research and development of ultra-early, precise, and safe tumor early detection products, as well as the comprehensive automation and digital upgrade of the detection process, aiming to provide more efficient, professional, and precise medical services for major hospitals, health check centers, and end customers. Its core product, Changyi Shu® colorectal cancer early non-invasive detection product, has been widely used in the market due to its excellent product performance and strict clinical validation.

Realbio has strong scientific research capabilities, and its R&D team has been conducting scientific research and breakthroughs with the intestinal microbiome as the core application direction. It has won the first prize of Shanghai Scientific and Technological Progress for the topic "Creation of Disease Classification Models for Gut Microbiota and Clinical Application of Microbiota Transplantation Therapy." Additionally, Realbio has deeply developed the application of artificial intelligence (AI) in disease early detection and personalized treatment, using innovative technology to promote the transformation of the medical and health industry towards intelligence, precision, and personalization.